Clinical trials: Epirubicin
Oesophagogastric Cancer
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cisplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- ST03 (NCT00450203)
- Testing
- bevacizumab, capecitabine, cisplatin
- Where
- 41 sites in United Kingdom
- Volunteers
- 1,103 people
- Sponsor
- Professor David Cunningham
Non-Muscle Invasive Bladder Urothelial Carcinoma
Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment
The goal of this clinical trial is to learn the dose-limiting toxicity of the new combined treatment with irinotecan liposomes (intravenous injection) and epirubicin (intravesical instillation) in anthracyclines treatment-failed…
- Trial name
- NCT06766266
- Testing
- Irinotecan liposome II combination therapy regimen
- Where
- China
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Breast Cancer
Catheter Guided Chemo-infusion in Breast Cancer
In the present prospective study, we will analyze the outcome of image-guided delivery of intra-arterially infused chemotherapeutic drugs for patients with breast cancer in III, IV stages.
- Trial name
- NCT05661656
- Testing
- Intra-arterial chemoinfusion of breast cancer
- Volunteers
- 50 people
- Sponsor
- Assiut University
Breast Cancer
Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- 12-93 (NCT00002529)
- Testing
- cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride
- Where
- 20 sites in Australia, Italy and 5 more
- Volunteers
- 452 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer, Chemotherapy
Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm
This is a multi-center randomized phase III trial. The purpose is to evaluate and compare the pathological complete response (pCR) rates after neoadjuvant chemotherapy with tailored chemotherapeutic regimens or standard…
- Trial name
- TaiNAC (NCT00776724)
- Testing
- Taxotere , Epirubicin, E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP
- Where
- Taiwan
- Volunteers
- 166 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
In this trial investigators propose to assess the dose dense, G-CSF supported sequential administration of 4 cycles of FEC followed by 4 cycles of docetaxel versus 6 cycles of docetaxel/cyclophosphamide as adjuvant chemotherapy…
- Trial name
- NCT01985724
- Testing
- Docetaxel, Epirubicin, Cyclophosphamide
- Where
- 10 sites in Greece
- Volunteers
- 650 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
This is a prospective, multisite, randomized, open-lable Phase III clinical trial (PATTERN study) comparing Paclitaxel Plus Carboplatin versus Anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative…
- Trial name
- NCT04031703
- Testing
- Paclitaxel, Carboplatin, Epirubicin
- Volunteers
- 647 people
- Sponsor
- Fudan University
Neutropenia, Breast Cancer
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
A Phase I, dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of F-627 in female breast cancer patients who received up to 4 cycles of Epirubicin and Cyclophosphamide.
- Trial name
- NCT02527746
- Testing
- F-627, EC regimen
- Volunteers
- 18 people
- Sponsor
- EVIVE Biotechnology
Breast Neoplasms
CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
Chemotherapy before operation for malignant tumors can reduce the size of tumors to a certain extent, even eliminate micrometastases.
- Trial name
- NCT04059003
- Testing
- Taxanes or/and anthracycline-based therapy
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Shengjing Hospital
Neutropenia
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
This was a randomized, open-label, active-controlled, dose-finding, phase II study to evaluate the efficacy and safety of 2 doses of F-627 compared to Filgrastim in women with breast cancer receiving myelotoxic chemotherapy.
- Trial name
- NCT02521441
- Testing
- F-627, Filgrastim
- Where
- China
- Volunteers
- 138 people
- Sponsor
- EVIVE Biotechnology
Newly Diagnosed Peripheral T-cell Lymphoma
Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Apatinib Combined With CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell lymphoma.
- Trial name
- NCT03631862
- Testing
- Apatinib, CHOP Regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhengzhou University
HCC
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC.
- Trial name
- NCT06844357
- Testing
- tirapazamine, Transarterial Embolization (TAE), TACE
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Breast Cancer
Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast
Although approximately 50% of new diagnosis breast cancers are in patients above the age of 65, elderly people remain substantially under-represented in clinical trials, and therefore are under-treated.
- Trial name
- ICE-II (NCT01204437)
- Testing
- Epirubicin, Cyclophosphamide, Cyclophosphamide, Methotrexate, 5 FU, Capecitabine, Nab-Paclitaxel
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer, Breast Cancer Female
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
This is a one stage phase II study with a single arm design. It will be conducted in HER-2 positive breast cancer patients in Nigeria who are chemotherapy/hormonal treatment naive.
- Conditions
- Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer, Breast Cancer Stage II
- Trial name
- NCT03879577
- Testing
- Docetaxel, Herceptin, FEC
- Where
- Nigeria
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Breast Adenocarcinoma
Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
The goal of this clinical trial is to compare the efficacy and safety in patients with lymph node-positive HR+/HER2- breast cancer.
- Trial name
- NEOTRIO-HR (NCT06671262)
- Testing
- SBRT, Immuno-chemotherapy
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lymphoma,Non-Hodgkin
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.
- Trial name
- NCT02996617
- Testing
- rhG-CSF regimen, Pegylated rhG-CSF regimen
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shandong Provincial Hospital
Triple Negative Breast Cancer
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
The study is being conducted to evaluate the efficacy, safety and tolerability of Camrelizumab Combination With Nab-Paclitaxel and Epirubicin as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04676997
- Testing
- Camrelizumab, Nab paclitaxel, Epirubicin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong Cancer Hospital and Institute
HER2-negative Breast Cancer
AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer
This is a prospective, randomized and open-label phase II study, evaluating the efficacy and safety of AT vs TP regimen as neoadjuvant treatment for early HER2-negative breast cancer.
- Trial name
- NCT04499118
- Testing
- AT regimen, TP regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sichuan Provincial People's Hospital
Urinary Bladder Neoplasms
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
The purpose of this study is to evaluate the safety and efficacy of applying cryoablation as an adjuvant therapy with TUR to treat bladder tumor.
- Trial name
- NCT02760953
- Testing
- Cryoablation, Epirubicin
- Volunteers
- 150 people
- Sponsor
- Huashan Hospital
Breast Cancer
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
This is an open-label study that includes two substudies of random distribution. First,a sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical technique to determine several markers.Depending…
- Trial name
- NCT00432172
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 12 sites in Spain
- Volunteers
- 189 people
- Sponsor
- Spanish Breast Cancer Research Group